Method of treating a disease or condition characterised by aberrant epithelial cell proliferation
A method is provided for treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration. One step of the method can include administering to a mammal an agent which disrupts an isolated protein complex including: insulin-like growth factor I (IGF-I); an insulin-like growth factor binding protein (IGFBP) selected from IGFBP-3 and IGFBP-5; and vitronectin; or which prevents formation of the isolated protein complex, to thereby treat the disease or condition in the mammal. The agent is selected from the group consisting a polypeptide that is distinguished from IGF-II by substitution of at least one amino acid residue, wherein the polypeptide disrupts the isolated protein complex.
1. A method of treating a disease or condition characterized by aberrant epithelial cell proliferation and/or migration, said method including the step of administering to a mammal an agent which disrupts a protein complex comprising: insulin-like growth factor I (IGF-I); an insulin-like growth factor binding protein (IGFBP) selected from IGFBP-3 and IGFBP-5; and vitronectin; or which prevents formation of the protein complex, to thereby treat said disease or condition in said mammal, wherein the agent is IGF-II comprising a conservative amino acid substitution, and wherein the polypeptide disrupts the protein complex.
2. The method of claim 1 , wherein the disease or condition characterized by aberrant epithelial cell proliferation and/or migration is a cancer.
3. The method of claim 1 , wherein the disease or condition characterized by aberrant epithelial cell proliferation and/or migration is associated with tumour metastasis.
4. The method of claim 1 , wherein the disease or condition characterized by aberrant epithelial cell proliferation and/or migration is psoriasis.
5. The method of claim 1 , wherein the disease or condition is characterized by aberrant epithelial cell proliferation and/or migration is epithelial breast cancer.
6. The method of claim 1 , wherein the disease or condition characterized by aberrant epithelial cell proliferation and/or migration is associated with tumour growth.